Since the disruption of GLP-1 [65] was proved to be one of the underlying causes of BED, and it is implicated in the hypothesis of the possible use of GLP-1 agonists as a part of the therapeutic strategy [79]. Here, GLP1R is linked to X-linked cone dysfunction syndrome with myopia.